Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

HMGA2 functions as a competing endogenous RNA to promote lung cancer progression

10:23 EST 5 Dec 2013 | Nature Publishing

Non-small-cell lung cancer (NSCLC) is the most prevalent histological cancer subtype worldwide. As the majority of patients present with invasive, metastatic disease, it is vital to understand the basis for lung cancer progression. Hmga2 is highly ex...

Original Article: HMGA2 functions as a competing endogenous RNA to promote lung cancer progression

NEXT ARTICLE

More From BioPortfolio on "HMGA2 functions as a competing endogenous RNA to promote lung cancer progression"

Search BioPortfolio:
Advertisement

Relevant Topics

Top five promising drugs Phase III (February 2014)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE III TRIALS February 2014 Drug Disease Company Lu-AE58054 Alzheimer’s disease H. Lundbeck / Otsuka Pharmaceutical Patisiran...

Gilotrif (afatinib)
Latest News Clinical Trials Research Drugs Reports Corporate
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Advertisement

Searches Linking to this Story